PC
AVXL icon

Pier Capital’s Anavex Life Sciences AVXL Stock Holding History

Pier Capital’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-415,906
Closed -$3.7M – 130
2025
Q3 		$3.7M Sell
415,906
-8,242
-2% -$83.6K 0.58% 85
2025
Q2 		$3.91M Sell
424,148
-31,279
-7% -$267K 0.6% 80
2025
Q1 		$3.91M Buy
455,427
+13,512
+3% +$128K 0.65% 74
2024
Q4 		$4.75M Buy
+441,915
New +$3.4M 0.68% 80
2023
Q1 		– Sell
-280,854
Closed -$2.6M – 110
2022
Q4 		$2.6M Sell
280,854
-103,957
-27% -$1.11M 0.43% 91
2022
Q3 		$3.97M Buy
384,811
+632
+0.2% +$6.67K 0.68% 73
2022
Q2 		$3.85M Sell
384,179
-104,515
-21% -$990K 0.66% 73
2022
Q1 		$6.02M Buy
488,694
+212,350
+77% +$2.61M 0.77% 74
2021
Q4 		$4.79M Buy
276,344
+161
+0.1% +$3.06K 0.51% 89
2021
Q3 		$4.96M Buy
+276,183
New +$5.5M 0.51% 93

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Pier Capital's AVXL Position: Q4 2025 in Review

Pier Capital sold out of Anavex Life Sciences (AVXL) in Q4 2025, closing a stake of 415,906 shares — an estimated $3.7M sold.

Pier Capital first reported a position in AVXL in Q3 2021 and held it in 10 quarters. The position peaked at $6.02M in Q1 2022. 184 funds tracked by Wall St. Rank hold AVXL as of Q4 2025.

  • Pier Capital reported no remaining Anavex Life Sciences position as of Q4 2025 after selling out during the quarter.
  • Pier Capital sold 415,906 Anavex Life Sciences shares in Q4 2025, an estimated $3.7M.
  • Pier Capital first reported a position in Anavex Life Sciences in Q3 2021 and held it in 10 quarters.
  • Pier Capital's Anavex Life Sciences position peaked at $6.02M in Q1 2022.
  • 184 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2025.

Based on Pier Capital's 13F filing for Q4 2025, filed 3 Feb 2026.